NY0116 is an agonist of the neuromedin U receptor 2 (NMUR2), exhibiting EC50 values of 27.76 μM for hNMUR1 and 13.61 μM for hNMUR2. In NMUR2 stably expressing HEK293 cells, NY0116 reduces cAMP levels while enhancing calcium signaling [1].

NY0116 exhibits a potent dose-dependent inhibitory effect on cAMP in HEK293 cells stably expressing hNMUR2, with an EC50 of 1.69 nM. Additionally, NY0116 stimulates calcium signaling within the cells [1].

NY0116 (3-30 mg/kg; subcutaneous; 14 days) significantly reduced body weight, visceral fat tissue, and cholesterol levels under a high-fat diet [1]. This study utilized male C57BL/6J mice aged 18 and 8 weeks with diet-induced obesity (DIO). The compound was administered subcutaneously at doses of 3, 10, and 30 mg/kg over a period of 14 days. Results indicated a significant reduction in body weight compared to the control group, despite maintaining a high-fat diet.